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Abstract Background:Although the efficacy of leukotriene receptor antagonists (LTRAs)
for bronchial asthma is already established, their effect on food allergy remains
unclear.
Objective: To investigate the efficacy of LTRAs in children with food allergy.
Methods: This retrospective study examined 65 children with food allergy who
were aged between 3 and 36 months (mean 14– 9.6 months) from 2005 to
2008. Thirty-two children were treated as a dietary control group by avoiding
any antigenic foods to which they had previously experienced adverse re-
actions. The remaining 33 children, designated the LTRA group, were treated
with pranlukast (7mg/kg bodyweight/day) in addition to maintaining dietary
control. Clinical symptoms and laboratory data before and after 1 year of
treatment were compared between the groups.
Results: Allergic symptoms improved in both the dietary controlled and
LTRA groups, and there was no significant difference observed in the clinical
parameters examined between the groups after the 1-year trial. Peripheral eosin-
ophil count, serum IgE, interleukin (IL)-4, IL-5, IL-6, and eosinophil cationic pro-
tein (ECP) levels in children with food allergy were above standardized values in
both groups. Although both the dietary controlled and LTRA groups showed a
decreased eosinophil count (-273– 232 vs -595– 295/mL; p< 0.05 and p< 0.001,
respectively), only children treated with LTRA showed a significant decrease in
serum IgE (-73.5– 115 IU/mL; p< 0.01); conversely, the control group exhibited
a significant increase in serum IgE (+159– 138 IU/mL; p< 0.01). Furthermore, the
LTRA group also showed a significant decrease in serum IL-4 (54.5– 31.0 to
27.3– 10.1pg/mL), IL-5 (6.7– 5.2 to 5.0– 0.4pg/mL), and ECP (45.4– 15.0 to
15.0– 9.8mg/L) levels (p< 0.05 for each).
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Conclusion: Early intervention with LTRAs may be effective in regulating
eosinophil count and serum IgE, IL-4, IL-5, and ECP levels. These data sup-
port the potential effectiveness of LTRAs in young children with food allergy
to prevent further allergic development.
Introduction
Food allergy is defined as an adverse response
initiated by the immune system to a specific food
antigen.[1-3] These adverse responses, including ana-
phylactic shock, can arise in many tissues of the
body, including the skin, conjunctiva, and gastro-
intestinal and respiratory tracts. In general, food
allergy occursmore commonly in younger children,
including infants.[2,4] After the age of 3 years, more
than 70% of these children are expected to be free
from allergic symptoms related to ingested foods,
known as ‘tolerance’.[4-9] After this time, they tend
to develop further allergic diseases, including asthma,
allergic rhinitis, and conjunctivitis with increased
levels of serum IgE. This sequential development of
allergic disease manifestations is often referred to as
the ‘atopic march’. It is considered that early inter-
vention in children with food allergy is important to
prevent development of the atopic march.[10]
Themost fundamentalmanagement of children
with food allergy in the acute phase is to prevent
them from ingesting any antigenic foods and
to provide foods in which antigens are decon-
structed, such as hydrolyzed formula in patients
with milk allergy.[11] When anaphylactic reactions
occur, exposure may be fatal for these children;
therefore, medical management that can reduce
or treat allergic symptoms arising from antigen
ingestion must be developed.
Cysteinyl leukotrienes (Cys-LTs) are potent
pro-inflammatory mediators derived from arachi-
donic acid through the 5-lypoxigenase pathway.
By competitive binding to the Cys-LT receptor,
a leukotriene receptor antagonist (LTRA) [e.g.
montelukast or pranlukast] blocks the effects of
Cys-LTs and alleviates the symptoms of many
chronic allergic diseases, including bronchial asth-
ma.[12] The clinical effect of montelukast for pe-
diatric asthma was first reported in 1998.[13] It has
been used since that time, and its effectiveness is
recognized worldwide.[14] Meanwhile, the effec-
tiveness of pranlukast, a novel LTRA developed
in Japan, for the treatment of asthma is also
confirmed in the Western world. A double-blind,
placebo-controlled, multicenter clinical study of
pranlukast in mild to moderate asthma was per-
formed in the US and Europe, and its safety and
tolerability were also established.[15,16] In Japan,
montelukast and pranlukast are used for the treat-
ment of asthma, and their effectiveness against
asthma is equally accepted.[17]
In this study, we investigated the efficacy of
LTRA in children with food allergy as an early
intervention, in terms of clinical outcome, eosin-




All study protocols were approved by the
Institutional Ethics Committee of Juntendo Uni-
versity Hospital, and informed consent for par-
ticipation was obtained from the parents of all
children prior to enrollment in the study.
This is a retrospective review of 65 children
with food allergy between the ages of 3 and
36months (mean 14– 9.6months) who underwent
dietary control with or without LTRA treatment
(table I). All patients were monitored at the Jun-
tendo University Hospital between the years of
2005 and 2008 under the diagnosis of food al-
lergy. No cases of parasitosis were confirmed
among these patients. The diagnosis of food al-
lergy was established by open food challenge test
and by confirmed adverse responses, such as di-
arrhea, vomiting, occult bloody stool, rash, ec-
zema, coughing, and wheezing, after antigenic
food ingestion under the physician’s supervision.
A total of 32 children were treated with dietary
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control only and assigned to the dietary controlled
group. The remaining 33 childrenwere treatedwith
LTRA in addition to the dietary control for 1 year
and assigned to the LTRA group. Dietary control
was performed according to the Japanese pediatric
guideline for food allergy 2005.[18] Dietary control
was applied through avoidance of foods that had
triggered the previously confirmed adverse reac-
tions. Routine clinical examination, with confirma-
tion of LTRA administration from the parents in
the LTRA group, was performed everymonth dur-
ing this study. During the study period, food chal-
lenge tests were conducted periodically to determine
if tolerance to specifically identified antigenic foods
had developed.Once tolerance had been established,
children were allowed to ingest antigenic foods in
small amounts.
Pranlukast (7mg/kg bodyweight/day) was ad-
ministered orally to the children in the LTRA
group. All children were allowed to use any drugs
including corticosteroid ointment, but any oral
administration of corticosteroids was temporarily
ceased. In addition, all children in the dietary con-
trolled group did not use any LTRAs during this
study. Before and at the end of the 1-year trial, we
performed statistical comparisons of clinical symp-
toms and the laboratory data, including peripheral
eosinophil count, and levels of serum IgE, cyto-
kines related to allergic reactions (interleukin [IL]-4,
-5, -6, transforming growth factor [TGF]-b1), and
eosinophil cationic protein (ECP). Clinical symp-
toms were evaluated as positive with confirmation
of occult bloody stool, diarrhea, vomiting, eczema,
rash, wheezing, failure to thrive, and anaphylaxis
after intake of food antigens at the time of physi-
cian observation (table II).
Determination of Serum Cytokine and
Eosinophil Cationic Protein Levels by ELISA
To determine serum cytokine and ECP levels
in children with food allergy, ELISA kits for
human IL-4 (R&D Systems Europe, Oxon, UK),
IL-5 (R&D Systems Europe), IL-6 (Fujirebio,
Table I. Characteristics of the population studied
Parameter Normal range Children with food allergy (n =65)a
dietary controlled group (n= 32) LTRA group (n =33)
Age (years) 1.2 – 0.8 1.3 – 0.8
Male/female (n) 20/12 24/9
Eosinophil (/mL) <450 950 –564 981 –537
IgE (IU/mL) <170 607 –585 612 –593
ECP (mg/L) <14.7 35.0 – 13.0 45.4 – 15.0
IL-4 (pg/mL) <13.9 49.9 – 29.4 54.5 – 31.0
IL-5 (pg/mL) <5 6.0 – 2.6 6.7 – 5.2
IL-6 (pg/mL) <0.7 2.3 – 2.2 2.2 – 3.0
TGF-b1 (ng/mL) <11 40.6 – 14.7 44.9 – 11.7
a Values are expressed as mean –SD. Mann-Whitney U-tests were performed, and no significant differences were found in age, eosinophil
counts, serum IgE, ECP, IL-4, IL-5, IL-6, or TGF-b1 levels between the groups. 2 ·2 chi-squared tests were performed, and no significant
differences were found in sex distribution between the groups.
ECP = eosinophil cationic protein; IL = interleukin; LTRA = leukotriene receptor antagonist; TGF = transforming growth factor.
Table II. Clinical symptoms before and after the triala








Bloody stool 6 0 5 0
Diarrhea 5 0 4 0
Vomiting 3 0 2 0
Failure to thrive 4 1 7 0
Eczema 13 3 16 4
Rash 5 1 6 1
Wheezing 4 1 4 1
Anaphylaxis 1 0 0 0
a Both the dietary controlled and LTRA groups showed reduced
allergic symptoms after the trial. 2 · 2 chi-squared and Fisher’s
tests were performed, and no significant differences were found
in reduced allergic symptoms between the groups.
LTRA = leukotriene receptor antagonist.
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Tokyo, Japan), TGF-b1 (R&D Systems Europe),
and ECP (Roche Diagnostic, Basel, Switzerland)
were used according to the manufacturers’ in-
structions. Each ELISA assay was performed in
triplicate.
Statistical Analysis
Because the majority of the data were not nor-
mally distributed, we used nonparametric anal-
ysis. Data were analyzed using Wilcoxon t-tests
when each value was compared before and after
the trial. The Mann-Whitney U-test, 2· 2 chi-
squared test, and Fisher’s exact test were used
to determine significant differences between the




At baseline, peripheral eosinophil count and
serum IgE, IL-4, IL-5, IL-6, and ECP levels in
children with food allergy were above the stan-
dard levels obtained from healthy children in our
facility (table I). Furthermore, there were no sig-
nificant differences in clinical symptoms, age, pe-
ripheral eosinophil count, and serum IgE and
cytokine levels between the dietary controlled and
LTRA groups before the trial (tables I–III).
Allergic symptoms following intake of a spe-
cific food antigen in these patients at baseline in-
cluded gastrointestinal symptoms, such as bloody
stool (11 cases, 17%), diarrhea (9 cases, 14%),
vomiting (5 cases, 8%), and failure to thrive
(11 cases, 17%); skin responses, such as eczema
(29 cases, 45%) and rash (11 cases, 17%); and res-
piratory symptoms, such as wheezing (8 cases,
12%) [table II]. Weanling infants showed more
symptoms that overlapped with gastrointestinal
tract symptoms. There was one child in the diet-
ary controlled group who experienced an ana-
phylactic reaction after antigen ingestion. There
were nine children who had food allergy in com-
bination with asthma, 29 with atopic dermatitis,
and none with allergic rhinitis.
Antigen-specific IgE antibodies were frequent-
ly detected at baseline against egg white (30 cases,
46%), cow’s milk (18 cases, 28%), wheat (11 cases,
17%), and soybean (11 cases, 17%) among all of
the patients. There were no significant differences
in antigen specificity between the dietary con-
trolled and LTRA groups in this study (table III).
Effects of LTRA
No patients experienced any adverse reactions
after the LTRA administration during this study.
The number of patients who showed specific al-
lergic symptoms after food ingestion was de-
creased after 1 year in both the dietary controlled
and LTRA groups (table II). There were 13 chil-
dren (40.6%) in the dietary controlled group and
15 children (45.5%) in the LTRA group who
established tolerance, confirmed by a food chal-
lenge test, to antigenic foods that were identified
at the beginning of this trial. However, there was
no significant difference between the dietary con-
trolled and LTRA group for these factors.
The peripheral eosinophil count was signi-
ficantly decreased in both the dietary controlled
(p < 0.05) and LTRA groups (p < 0.001) after the
trial (figure 1). However, the decrease in peripheral
eosinophil counts was significantly greater in the
LTRA group (mean– SD, control -273– 232/mL;
LTRA -595– 295/mL, p< 0.05) [figure 2a].
Serum IgE levels in the dietary controlled
group significantly increased (p < 0.01) despite re-
duced symptoms after the trial, whereas levels in
the LTRA group had significantly decreased after
the treatment (p < 0.01) [figure 1]. There was a sig-
nificant difference in the change in serum IgE lev-
Table III. Antigen-specific IgE antibodies before and after the triala




before trial after 1 year before trial after 1 year
Egg white 13 9 17 10
Ovomucoid 4 3 6 4
Cow’s milk 8 4 10 6
Wheat 5 4 6 4
Soybean 4 2 7 2
a Both the dietary controlled and LTRA groups showed decreased
specific IgE after the trial. 2 ·2 chi-squared and Fisher’s tests
were performed, and no significant differences were found in
antigen-specific IgE levels between the groups.
LTRA = leukotriene receptor antagonist.
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els between the LTRA group (-73.5– 115 IU/mL)
and the dietary controlled group (+159– 138 IU/mL)
[p< 0.01; figure 2b]. Serumantigen-specific IgE levels
decreased in both groups, and there was no sig-
nificant difference confirmed between the groups in
each level (table III). Furthermore, there were sig-
nificant decreases in serum ECP (from 45.4– 15.0











































































Fig. 1. (a) Peripheral eosinophil counts and (b) serum IgE levels before and after the trial in the dietary controlled and leukotriene receptor
antagonist (LTRA) groups. The peripheral eosinophil count was significantly decreased after 1 year in the dietary controlled and LTRA groups.
The serum IgE level of the dietary controlled group was significantly increased, whereas that of the LTRA group was significantly decreased























































Fig. 2. Change in (a) peripheral eosinophil counts and (b) serum IgE levels during the trial in the dietary controlled and leukotriene receptor
antagonist (LTRA) groups. The decrease in peripheral eosinophil counts was significantly greater in the LTRA group when compared with that
in the dietary controlled group. The decrease in serum IgE levels in the LTRA group was significantly different from the increase in the dietary
controlled group. Data were analyzed using the Mann-Whitney U-test. * p < 0.05, ** p < 0.01.
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27.3– 10.1pg/mL), and IL-5 (from 6.7– 5.2 to
5.0– 0.4pg/mL) levels after treatment with LTRA
(p< 0.05 for each), but there was no significant
change inECP (from35.0– 13.0 to 25.4– 12.8mg/L),
IL-4 (from 49.9– 29.4 to 35.3– 15.1pg/mL), or IL-5
(from 6.0– 2.6 to 5.3– 1.0pg/mL) in the dietary
controlled group after 1 year (figure 3).
Discussion
The present study demonstrates the effective-
ness of LTRA treatment in children with food
allergy by showing a significant decrease in peri-
pheral eosinophil count and serum IgE, IL-4, IL-5,
and ECP levels. Since IL-4 stimulates IgE synthe-
sis and IL-5 promotes eosinophil migration lead-
ing to enhanced allergic reactions, LTRA treat-
mentmay protect young childrenwith food allergy
from further allergic development. Although the
clinical benefit was not confirmed after 1 year of
LTRA administration in this study, it may be pos-
sible to confirm its clinical benefits with longer
duration.
Eosinophils and mast cells produce Cys-LT,
which has several effects on local tissues, includ-
ing eosinophil activation and migration. LTRA,
which inhibits Cys-LTs, is also reported to sup-
press the production of Cys-LTs (e.g. leukotriene
C4 [LTC4] and leukotriene D4), cytokines (e.g.
IL-4 and IL-5), and the expression of nuclear
factor-kB (NF-kB), as well as eosinophil activa-
tion, leading to reduced eosinophilic migration
into local tissue.[19-23] The Cys-LT1 receptor an-
tagonists montelukast and pranlukast are well
known to have clinical benefits for the treatment
and management of allergic diseases, particular-
ly asthma. Several studies have suggested that
pranlukast inhibits lipopolysaccharide-induced
IL-6, allergen-specific tumor necrosis factor-a
(TNFa) and T helper-2 (Th2)-type cytokine pro-
duction and the translocation of NF-kB, a ubiq-
uitous transcription factor for genes that encode
pro-inflammatory cytokines such as IL-1, IL-6,
IL-8, and TNFa.[24-26] Clinical allergic symptoms
as well as eosinophil count, serum IgE, and IL-4
levels have been shown to drop significantly after
LTRA treatment in children with allergic rhinitis
and Kimura’s disease.[27-29] The effectiveness of
LTRAs was also reported in allergic eosinophilic
esophagitis, a rarely diagnosed condition involv-
ing eosinophil infiltration of the esophageal mu-
cosa among infants.[30]
Serum IgE levels were significantly increased
in the control group as a natural course of illness
despite dietary treatment, but were significantly
decreased in the LTRA group. These results
suggest that early intervention with LTRA may















































Fig. 3. Serum eosinophil cationic protein (ECP) and pro-inflammatory cytokine levels before and after the trial in the (a) dietary controlled and
(b) leukotriene receptor antagonist (LTRA) groups. The serum ECP, interleukin (IL)-4, and IL-5 levels in the LTRA group were significantly
decreased after the LTRA treatment. Data were analyzed using Wilcoxon t-tests. Results are means –SD. TGF = transforming growth factor;
* p <0.05.
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IgE synthesis, possibly by regulating eosinophil
migration and Th2-type cytokine production.
Ohshima et al.[22] have reported that intracrine
Cys-LT receptor-mediated signaling induced by
LTC4 acts as an intracrine mediator of eosinophil
IL-4 secretion. Our findings also suggest that
LTRA is beneficial in the clinical management
of children with food allergy by attenuating IL-4
and IL-5 production. As IL-4 and IL-5 are im-
portant cytokines in IgE synthesis and eosinophil
migration, LTRAmay reduce the present allergic
symptoms as well as preventing further progres-
sion of allergic inflammation in children through
this mechanism of action. Since the improvement
of laboratory data is different from the preventive
effect on the allergic diseases, further study is
necessary to prove the potential effects of LTRAs
in regulating the development of allergic diseases.
In this study, we focused on children with food
allergy who were under 3 years of age and who
were administered LTRA as an early intervention.
These children have weaker intestinal function in
terms of digestion and tight junction development,
which results in a greater intestinal permeability
than adults.[31] In the presence of eosinophilia, eo-
sinophil degranulation can further increase intes-
tinal permeability and enhance transmigration of
undigested peptides from the intestinal lumen to
the systemic circulation,[32] which may cause these
children to develop allergic reactions more easily.
Because young children often show eosinophilia,
this condition can be a risk factor for them to de-
velop future allergic diseases. Furthermore, since
elevated levels of ECP were confirmed in children
with food allergy, regulating eosinophil migration
into the intestine and reducing the total amount of
ECP secreted from eosinophils by LTRA treat-
ment may possibly protect children with food al-
lergy from further allergic progression.
Conclusion
Although the clinical benefit of pranlukast was
not confirmed after this 1-year trial, these results
suggest that early intervention with LTRA is ef-
fective in regulating eosinophil count and serum
IgE, IL-4, IL-5, and ECP levels; with long-term
use, LTRA may also be effective in preventing
further allergic development, especially in young
children with food allergy. Further study is neces-
sary to confirm the potential use of LTRA in the
prevention of allergic inflammation in children
with food allergy.
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